With an expiration date still more than a year away, here's what the latest details reveal.
It has long been assumed that psychostimulants help those with ADHD by acting on the brain’s attention circuitry. However, new research finds that this is not the case.
FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.
GlobalData on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
Women are driving soaring use of ADHD medication, experts say. Researchers from the University of Oxford highlighted a 20-fold rise in use of drugs to manage the condition among w ...
Finding the right ADHD prescription can feel overwhelming at first. With dozens of stimulant and nonstimulant ADHD medications available, many people search for clarity on how these medications work, ...
Changes proposed by the Allan government will seek to cut down a process that can take up to a year and costs at least $2000.
From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.
Please provide your email address to receive an email when new articles are posted on . Asian, Black and Hispanic children with ADHD were less likely to be prescribed medication early vs. white ...
ADHD New Zealand spokesperson Darrin Bull joins Mike Hosking to discuss the significant prescription law change that will make ADHD treatment easier to acc ...
A new model of care is needed to reduce waiting lists for children with attention deficit hyperactivity disorder (ADHD) and other neurodivergent conditions who are often “pushed to the back of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results